ArticleInternational journal of women's health2026
Development and Validation of a Multi-Omics Model Integrating US-Derived and WSI-Based Features to Predict Lymph Node Metastasis in Ovarian Cancer: A Multi-Center Retrospective Study.
Article in International journal of women's health, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: The study aims to develop and validate a multi-omics model based on preoperative ultrasound (US) imaging results, intraoperative H&E- stained slides, and clinical features to predict lymph node metastasis (LNM) before lymph node dissection (LND) in ovarian cancer (OC) patients. Methods: We analyzed 157 OC patients undergoing LND with definitive pathological confirmation of LNM status, comprising 91 patients in the training cohort, 38 in the internal validation cohort, and 28 in the external test cohort. US images were processed with PyRadiomics to extract radiomics features, while pathological WSIs were processed with deep learning (DL) algorithms and multi-instance learning(MIL) algorithms to extract pathomics features. Then, radiomics and pathomics models were developed using support vector machines (SVMs), logistic regression (LR), and extreme gradient boosting (XGBoost) after dimensionality reduction and feature selection. To create a powerful multi-omics model, clinical features were incorporated into the optimal radiomics and pathomics features. Performance of models was assessed by accuracy, AUC, 95% CI, sensitivity, specificity, PPV and NPV. Results: A total of 11 features were used to build radiomics models out of a selection of 1561 radiomics features. The SVM_rad model demonstrated superior predictive performance (AUC: training=0.816, validation=0.760, test=0.775). In parallel, pathomics models were built using a refined set of 3 features selected from the original 206 pathomics features. Among these, the SVM_path model showed the highest predictive efficiency (AUC: training=0.983, validation=0.817, test=0.813). The multi-omics model showed the greatest discriminative power (AUC: training=0.988; validation=0.923; test cohort=0.862). The quality of the prediction model was demonstrated by the DeLong test, calibration curves, and decision curve analysis, which verified its high discrimination, calibration, and clinical usefulness. Conclusion: The study's findings indicate that the multi-omics model integrating the tumor-level radiological data, cellular-level pathological information, and patient-level clinical features can predict LNM before LND in OC and support rational treatment plans.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.